Pannu Geraldine 4

What Happened Geraldine Pannu, a director of Processa Pharmaceuticals, acquired 2,072 shares on March 31, 2026, at $2.54 per share for a total cost of approximately $5,253. The Form 4 lists the transaction as a purchase (code P), meaning shares were acquired rather than sold or received as compensation.

Key Details

• Transaction date: 2026-03-31; Price: $2.54 per share; Shares acquired: 2,072; Total value: ~$5,253.
• Transaction type: Purchase (SEC code P) — listed as an open market or private purchase in the filing excerpt.
• Filing date: 2026-04-01 (Form 4 accession 0000897069-26-000752). This filing appears to be within the typical SEC reporting window.
• Shares owned after the transaction: Not disclosed in the provided excerpt — check the full Form 4 for post-transaction holdings.
• No 10b5-1 plan, tax withholding, or other footnotes were provided in the data you shared.

Context This was a straightforward buy (not an option exercise, gift, or award). While insider purchases can be interpreted as a positive signal of confidence, this particular purchase is modest in dollar size; interpret it alongside other insider activity and company fundamentals. For full details (post-transaction holdings, any footnotes, or plan-based trades), review the complete Form 4 filing on the SEC EDGAR site.